



Noxopharm Limited (ASX:NOX)

WEBINAR PRESENTATION

DECEMBER 2020

Discover



Develop



Deliver



Disclaimer



This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.


Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Our single-minded objective



- is to prove that **Veyonda[®]**
- is the answer to unlocking the power of the immune system to fight cancer
- allowing the 3 main forms of cancer therapy - **immuno-oncology, radiotherapy, chemotherapy** - to reach their full potential
- identifying **Noxopharm** as a highly valuable industry partner

Key R&D achievements in 2020



We go into 2021



- with a strong cash position

*(based on **\$23M** CR and anticipated R&D Rebate)*

- providing a full 12-month runway

- to meet aim of attaining proof-of-concept of **Veyonda** as a major new drug prospect

Veyonda joins the new wave of cancer immuno-oncology (I-O) therapies



- ▮ that aim to restore the body's immune system to fight cancer


- ▮ are the acknowledged future of cancer therapy

- ▮ re-activating the immune system is readily achieved

- ▮ the problem is getting the reactivated immune cells back inside the tumours where they can kill the cancer cells


- ▮ the challenge facing the current US\$30 billion p.a. I-O therapy market is that most human tumours block that re-entry. NOX believes **Veyonda** is the leading candidate to overcome this problem

Restoring immune function to tumours




All healthy tissues contain immune cells (T cells)

whose role is to detect and eliminate any abnormal cells



Emerging cancer cells


produce high levels of S1P (**sphingosine-1-phosphate**) that drive the immune cells out of the tissue



With tumour now fully established, ongoing high S1P levels keep immune cells excluded

Cancer cells now free to grow in the absence of immune cells

= **COLD tumour**



Veyonda®


Veyonda block S1P production by cancer cells

With S1P levels down and the shield removed, immune cells now enter and repopulate the tumour

Immune cells now able to kill cancer cells

= **HOT tumour**

Employing the unique 'COLD to HOT' **Veyonda** function



Source: *Enhancing Immunotherapy: The Race to Make "Cold" Tumors "Hot"*. <https://blog.dana-farber.org/insight/2018/06/enhancing-immunotherapy-race-make-cold-tumors-hot/>

PD-1
therapy

IONIC Program
Veyonda + checkpoint (PD-1) inhibitors

Radio-
therapy

DARRT Program
Veyonda + (external beam) radiotherapy


Radio-
therapy

LuPIN Program
Veyonda + (intravenous) radiotherapy


Chemo-
therapy

CEP Program
Veyonda + chemotherapy

Employing the unique 'COLD to HOT' **Veyonda** function



Source: Enhancing Immunotherapy: The Race to Make "Cold" Tumors "Hot". <https://blog.dana-farber.org/insight/2018/06/enhancing-immunotherapy-race-make-cold-tumors-hot/>



PD-1
therapy

IONIC Program Veyonda + checkpoint inhibitors



2019 sales of checkpoint inhibitors **US\$22 billion**

- Keytruda® Merck
- Opdivo® Bristol-Myers Squibb
- Yervoy® Bristol-Myers Squibb

10-30% response rates in 7 cancers (eg. lung, melanoma, kidney, bladder)

<5% response rates in most other cancers

COLD tumours identified as major cause of non-response

Major Licensing and M&A activity to achieve higher response rates shifting sales to predicted US\$100 + billion p.a.

Search for Checkpoint Inhibitor partners




Fig. 1 | Trends in immuno-oncology drug licensing. 2018 was the biggest year yet for immuno-oncology (IO) drug licensing in terms of deal size and volume. IO licensing deal size increased in value by 51% from 2017 to 2018, while volume increased by 8%. Only licensing deals for drugs or drug platforms applicable to IO therapeutics were included. Data from Cortellis Deals Intelligence from Clarivate Analytics.

2018 15x Licensing Deals > US\$1 billion

Buyer	Seller	Total deal value
BMS	Nektar Therapeutics	US\$3,630 B
Merck	Eisai	US\$5,755 B

PD-1
therapy

IONIC Program
Veyonda + checkpoint inhibitors



IONIC-1

Veyonda® +
checkpoint
inhibitor



Immuno-Oncology With NOX66 In Combination

Veyonda® + nivolumab (Opdivo®)
(Bristol Myers Squibb)

Bristol-Myers Squibb	(NYSE:BMJ)
Market cap	US\$145 billion
Pharma ranking	11th
2019 sales	US\$26 billion
2019 Opdivo sales	US\$8 billion
2019 Celgene acquisition	US\$74 billion

A Phase I/II study involving both NOX and Bristol-Myers Squibb

PD-1
therapy

IONIC Program
Veyonda + checkpoint inhibitors



IONIC-1



Phase I/II study
Investigator-initiated
~30 patients
3 Australian hospitals
Early-Q1 2021 start

Clinical objective #1

Improve low (10-30%) response rates to Opdivo in responsive cancers (eg. lung, melanoma, bladder, kidney)



Cohort 1. Patients recently treated with Opdivo® with mild disease progression

Clinical objective #2



Achieve responses in remaining cancers where Opdivo® not currently used due to very poor response rates (eg. prostate, ovarian, pancreatic, sarcoma etc)



Cohort 2. Opdivo® naive patients

Direct and Abscopal Response to Radiotherapy

Transforming a local anti-cancer effect of radiation into a whole-of-body anti-cancer effect (**abscopal response**)



Objectives:

1. To convert the **abscopal response** from a very rare phenomenon (< 1 in 100,000) to a more commonplace event (~50% of cancer patients)
2. To produce long-term remission in metastatic cancers where survival prospects currently are poor

Radio-therapy

DARRT Program
Veyonda + (external beam) radiotherapy




DARRT Program

Radiotherapy


4-step DARRT process:

- Step 1.** Radiation applied to single tumour
- Step 2.** Radiation activates immune cells
- Step 3.** Veyonda augments that local immune response
- Step 4.** Veyonda then spreads that immune response to all other tumours throughout the body



Resolution of Irradiated tumour

Standard response



Partial abscopal response

Complete abscopal response

Abscopal response

Radio-
therapy

DARRT Program
Veyonda + (external beam) radiotherapy




DARRT-1 Completed 25 men late-stage progressive prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC)

No remaining standard treatment options

Low-dose (palliative) radiotherapy (RT) to single soft tissue tumour

Treatment with low-dose RT (5 days) and Veyonda® (14 days)



Bone scan with
metastatic disease

Radio-
therapy

DARRT Program
Veyonda + (external beam) radiotherapy



In patients evaluable after 6 months*

Over 50%
drop in
PSA in
5/16
patients

Over 30%
drop in
pain
levels in
10/16
patients

No
tumour
growth
in 10/15
patients

Abscopal
response
in 4/15
patients

* 15 patients eligible for RECIST; 16 for PSA and pain

2020 Noxopharm. All rights reserved.

Radio-
therapy

DARRT Program
Veyonda + (external beam) radiotherapy



DARRT-2 Phase 2 study 150 - 200 patients multi-national Parexel CRO

Late-stage cancer. No remaining standard treatment options

Final planning current. Enrolment to start H1 2021

Prostate cancer, breast cancer, lung cancer

Boosted therapy compared to DARRT-1 (2400 mg vs 1200 mg; multiple cycles of Veyonda vs 1 cycle)

Radio-
therapy

LuPIN Program
Veyonda + (intravenous) radiotherapy



LuPIN program = **Veyonda** + ¹⁷⁷**lutetium-PSMA-617** for late-stage prostate cancer

¹⁷⁷**lutetium-PSMA-617** acquired by **Novartis** in 2018 in **US\$6 billion** transaction

St Vincent's Hospital Sydney testing ability of LuPIN therapy to boost modest survival effect of Novartis drug alone

LuPIN-1 = Phase 2 study in 56 men with late-stage cancer that has progressed on all forms of therapy

First report of median overall survival from first **32 men (400/800 mg Veyonda)** highly encouraging at **17.1 months**

Median overall survival from all **56 men (400/800/1200 mg Veyonda)** to be reported **Feb 2021**

Objectives

Over the next 2.5 years, with a modest investment of shareholder funds, to show that ...

IONIC

Veyonda increases the response rate to **nivolumab (Opdivo)** (BMS), establishing its potential to boost checkpoint inhibitor drug sales well above current US\$22 billion p.a.

DARRT

Veyonda + **radiotherapy** and the abscopal response is a valid, cost-effective alternative form of I-O treatment for a range of solid cancers

LUPIN

Veyonda boosts the response rate in advanced prostate cancer to **¹⁷⁷Lu-PSMA-617** (Novartis)

PHARMORAGE

The Company's technology platform holds the potential to develop a family of new drugs for the treatment of septic shock, inflammatory diseases and autoimmune diseases

So building a highly valuable and compelling acquisition/partnering target

Discover



Develop



Deliver



An I-O therapy to transform the management of cancer

www.noxopharm.com

Email: info@noxopharm.com

Phone: (+61) 2 9144 2223



<https://www.linkedin.com/company/noxopharm-limited>



<https://twitter.com/noxopharm>

Media Enquiries

The Capital Network

Julia Maguire

+61 2 8999 3699

julia@thecapitalnetwork.com.au